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Purpose: To evaluate the efficacy and tolerability of tamsulosin 0.4 mg once daily in 
Korean patients with symptomatic benign prostatic hyperplasia (BPH) and investigate 
whether tamsulosin 0.4 mg can improve symptoms in patients with refractory lower 
urinary tract symptoms (LUTS) who were previously receiving tamsulosin 0.2 mg once 
daily. 
Materials and Methods: A total of 116 patients from 3 urology centers participated. All 
study subjects entered a nonblind phase consisting of 8 weeks of tamsulosin 0.2 mg mon-
otherapy followed by an additional 8 weeks of tamsulosin 0.2 mg (0.2 mg group) or 8 
weeks of tamsulosin 0.4 mg (0.4 mg group). At week 8, we chose the 0.4 mg group on 
the basis of International Prostate Symptom Score (IPSS), quality of life (QoL), max-
imal urinary flow rate (Qmax), and adverse effects. At week 16, we compared the efficacy 
and tolerability of tamsulosin between the 0.2 and 0.4 mg groups.
Results: A total of 26 patients (22.4%) were escalated to tamsulosin 0.4 mg at week 8. 
There were significant differences in IPSS, QoL, and Qmax at week 8 in both groups. 
There were significant differences in improvement in IPSS, QoL, Qmax, and postvoid 
residual urine volume from baseline to week 16 in both groups. There were no significant 
differences in efficacy or tolerability between the groups at week 16.
Conclusions: Our trial demonstrated that tamsulosin 0.4 mg has favorable efficacy and 
tolerability in Korean patients with symptomatic BPH refractory to tamsulosin 0.2 mg. 
No patients experienced any serious adverse effects when we escalated the dose of tam-
sulosin to 0.4 mg.
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INTRODUCTION
Lower urinary tract symptoms (LUTS) suggestive of be-
nign prostatic hyperplasia (BPH) are a common condition 
in older men. In epidemiological community-based sur-
veys, approximately 25% of men aged 40 years and over in-
dicate that they have LUTS [1-3]. Clinical BPH can inter-
fere with daily activities and diminish health-related qual-
ity of life specific to urinary symptoms. Treatment options 
include watchful waiting or lifestyle modification, herbal 
preparations, prescription medications, and surgical pro-
cedures. Medical management of BPH is the first ther-
apeutic option for many patients with symptomatic BPH 
[3]. The overall goal of the medical management of BPH in-
volves improving short-term symptoms, minimizing ad-
verse effects of treatment, and eventually preventing com-
plications and preserving quality of life. At present, al-
pha-1-adrenergic receptor antagonists (alpha-blockers) 
and 5-alpha-reductase inhibitors (5-ARIs) are the only rec-
ommended medical treatments for BPH [4,5]. Alpha-bloc-
kers improve symptoms and increase the urinary flow rate 
by relaxing prostatic and bladder neck smooth muscle Korean J Urol 2011;52:479-484
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FIG. 1. Study design: tamsulosin 0.2 
mg once daily monotherapy for 8 
weeks followed by 8 weeks of addi-
tional tamsulosin 0.2 mg once daily or
tamsulosin 0.4 mg once daily mono-
therapy.
through sympathetic activity blockade. 
　Alpha-blockers are the most common prescription medi-
cations and include doxazosin, terazosin, prazosin, alfuzo-
sin, and tamsulosin [6,7]. The alpha-1-adrenergic receptor 
appears to be the subtype mainly mediating prostate and 
bladder smooth muscle tone. Thus, they improve the dy-
namic component of bladder outlet obstruction (BOO) and 
can rapidly relieve LUTS. Unlike the other common al-
pha-blockers that are not selective for this subtype, such 
as doxazosin, alfuzosin, and terazosin, tamsulosin has 
high alpha-1a-adrenergic receptor affinity [7]. Because of 
this prostate selectivity, tamsulosin may improve urinary 
symptoms and flow with fewer adverse effects. Many stud-
ies have shown the efficacy and tolerability of tamsulosin 
at doses of 0.2 to 0.8 mg once daily in patients with sympto-
matic BPH. Seven trials were performed in Asia: 5 in 
Japan, 1 in China, and 1 in Korea. These studies were trials 
of tamsulosin 0.2 mg [8-10]. 
　In our trial, we investigated whether tamsulosin 0.4 mg 
once daily can improve Korean patients with refractory 
LUTS suggestive of BPH who were previously receiving 
tamsulosin 0.2 mg once daily. Also, we investigated wheth-
er when making treatment decisions for Korean patients 
with symptomatic BPH, who are receiving tamsulosin 0.2 
mg or 0.4 mg, we should incorporate evidence on con-
venience and dose-related efficacy versus adverse effects.
MATERIALS AND METHODS
This study was a nonblinded, open-label, multicenter, pro-
spective trial. From September 2009 to September 2010, 
a total of 133 patients from the outpatient clinics of three 
centers participated in this trial. In total, 116 patients were 
evaluated who were diagnosed as having symptomatic 
BPH and could be serially followed by our clinical trials. No 
patients had any life-threatening conditions such as acute 
cardiovascular disease, neurologic disease, or uncontroll-
ed hypertension or diabetes mellitus. All patients con-
sented to the purpose of the study and to the study itself 
after explanation. Informed consent was obtained from 
each subject, and the study was approved by the Institutio-
nal Review Board of each center. 
　On the patients’ first visit to the outpatient clinics, blood 
samples were taken from all patients for measurement of 
serum prostate-specific antigen (PSA) including serum 
chemical battery, and the International Prostate Symptom 
Score (IPSS), transrectal ultrasonography (TRUS), and ur-
oflowmetry were completed for all patients. Also, blood 
pressure and pulse rate were checked, and a digital rectal 
examination and routine physical examination were 
performed. 
　All patients with BPH eligible for treatment with tamsu-
losin were indicated in the locally approved prescribing 
information. The decision to enter the patient into the 
study must have been made after the clinical decision on 
the basis of the following inclusion criteria: patient’s age 
≥50 years, good overall mental and physical health, IPSS 
≥8 and maximal urinary flow rate (Qmax) ≤12 ml/s, and 
prostate volume ≤40 ml as determined by TRUS. 
Excluded were patients aged less than 50 years; patients 
judged to be inappropriate for a clinical trial; patients with 
urinary tract infection, urethral stricture, or neurogenic 
bladder; patients diagnosed with or thought to have pros-
tate or bladder cancer; and patients with a history of any 
urethral or prostate operation.
　All study subjects entered a nonblinded phase consisting 
of 8 weeks of tamsulosin 0.2 mg once daily monotherapy fol-
lowed by an additional 8 weeks of tamsulosin 0.2 mg 
(maintenance therapy) monotherapy or 8 weeks of tamsu-
losin 0.4 mg once daily (dose-escalating therapy) mono-
therapy. At week 8, we estimated the efficacy and toler-
ability of tamsulosin 0.2 mg monotherapy according to the 
clinical presentation of BPH. We then chose the tamsulosin 
0.4 mg group on the basis of the following criteria: improve-
ment of IPSS ＜20% or improvement of Qmax ＜20% or ag-
gravation of IPSS/quality of life (QoL) or development of 
clinically significant complications (Fig. 1). At week 16, we 
compared the improvement in the efficacy variables be-
tween the 0.2 mg group (tamsulosin 0.2 mg once daily for 
16 weeks) and the 0.4 mg group (tamsulosin 0.2 mg once 
daily for 8 weeks＋tamsulosin 0.4 mg once daily for an addi-
tional 8 weeks). In addition to these variables, the safety 
and tolerability of the treatment arms were evaluated by 
monitoring IPSS, QoL, Qmax, adverse events, clinical lab-
oratory tests, and routine physical examinations. All stat-
istical analyses were performed by using SPSS ver. 18.0 
(SPSS Inc., Chicago, IL, USA), and p＜0.05 was considered 
statistically significant (unpaired t-test, paired t-test, 
Fisher’s exact test).
RESULTS
Of the 116 patients who were evaluated for this study, a to-
tal of 26 patients (26/116, 22.4%) were escalated to tamsu-
losin 0.4 mg. The patients’ mean age was 62.1±4.9 years, 
their mean body mass index (BMI) was 24.1±5.6 kg/m
2, Korean J Urol 2011;52:479-484
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TABLE 2. Comparison of 0.2 mg group (tamsulosin 0.2 mg once 
daily) and of 0.4 mg group (tamsulosin 0.4 mg once daily) in 
improvement in IPSS, QoL, Qmax, and PVR
Mean±SD
p-value
0.2 mg group 0.4 mg group
IPSS
    Baseline
    8 weeks
    12 weeks
    16 weeks
QoL
    Baseline
    8 weeks
    12 weeks
    16 weeks
Qmax (ml/sec)
    Baseline
    8 weeks
    12 weeks
    16 weeks
PVR (ml)
    Baseline
    8 weeks
    12 weeks
    16 weeks
23.8±7.0
17.1±3.7
17.0±4.4
16.8±4.5
 5.0±0.9
 3.6±0.7
 3.5±0.6
 3.3±0.7
 7.9±2.6
10.6±2.1
11.1±2.7
12.8±2.0
 20.8±21.3
 16.0±22.8
 15.8±20.0
 13.5±17.7
22.4±5.3
21.9±3.7
17.8±3.2
17.4±3.4
 5.3±0.6
 5.0±0.6
 4.2±0.4
 3.5±0.8
 7.4±1.9
 8.3±2.1
11.1±2.1
12.6±2.4
 19.6±21.3
 15.2±17.6
 15.4±22.1
 12.7±20.5
  0.210
＜0.001
  0.257
  0.481
  0.175
＜0.001
＜0.001
  0.235
  0.480
＜0.001
  0.445
  0.768
  0.797
  0.366
  0.937
  0.864
IPSS: International Prostate Symptom Score, QoL: quality of life,
Qmax: maximal urinary flow rate, PVR: postvoid residual urine 
volume
TABLE 1. Demographics and other baseline characteristics
Mean±SD
p-value
0.2 mg group 0.4 mg group
Number of patients
Age (yr)
BMI (kg/m
2)
Initial serum PSA
  (ng/ml)
Prostate volume (ml)
90
62.6±7.3
24.4±5.5
  2.4±3.6
27.1±7.1
26
60.3±8.5
23.2±6.0
  2.5±3.3
28.1±4.4
0.235
0.104
0.888
0.467
BMI: body mass index, PSA: prostate-specific antigen, SD: stan-
dard deviation
TABLE 3. Mean changes in IPSS, QoL, Qmax, and PVR from 
baseline to weeks 8 and 16
Mean±SD
p-value 0.2 mg 
group
0.4 mg 
group
Mean change in IPSS
    From baseline to week 8
    From baseline to week 16
Mean change in QoL
    From baseline to week 8
    From baseline to week 16
Mean change in Qmax (ml/sec)
    From baseline to week 8
    From baseline to week 16
Mean change in PVR (ml)
    From baseline to week 8
    From baseline to week 16
−6.7±6.1
−7.0±6.2
−1.4±1.3
−1.7±1.2
  2.8±2.6
  4.9±3.4
−5.1±14.1
−7.4±16.4
−0.5±3.8
−5.1±5.2
−0.3±0.8
−1.8±1.0
  0.8±2.5
  5.2±3.5
−4.2±15.0
−6.9±15.2
＜0.001
  0.164
＜0.001
  0.827
＜0.001
  0.752
  0.791
  0.897
IPSS: International Prostate Symptom Score, QoL: quality of 
life, Qmax: maximal urinary flow rate, PVR: postvoid residual 
urine volume
their mean initial serum PSA was 2.5±2.1 ng/ml, and their 
mean prostate volume was 27.4±12.7 ml. There were no sig-
nificant differences in mean age, BMI, initial serum PSA, 
or prostate volume between the tamsulosin 0.2 mg group 
and the 0.4 mg group (Table 1). The follow-up period for all 
patients was 16 weeks (Fig. 1). 
　The mean IPSS of the 0.2 mg group at baseline, 8, 12 and 
16 weeks was 23.8±7.0, 17.1±3.7, 17.0±4.4, and 16.8±4.5, 
respectively, and the mean IPSS of the 0.4 mg group at 
baseline, 8, 12, and 16 weeks was 22.4±5.3, 21.9±3.7, 
17.8±3.2, and 17.4±3.4, respectively (Table 2). There were 
significant differences between the two groups in the IPSS 
and the mean change in the IPSS from baseline at week 8 
(p＜0.001) (Table 2, 3). In both groups, there were sig-
nificant differences between the IPSS at baseline and that 
at week 16 (p＜0.001) (Fig. 2, 3). At week 16, the mean 
change in the IPSS from baseline was −7.0±6.2 and −5.1± 
5.2 in the 0.2 and 0.4 mg groups, respectively, and there 
were no significant differences in the mean change in the 
IPSS between the two groups (p=0.164) (Table 3). 
　The mean QoL of the 0.2 mg group at baseline, 8, 12, and 
16 weeks was 5.0±0.9, 3.6±0.7, 3.5±0.6 and 3.3±0.7, re-
spectively, and the mean QoL of the 0.4 mg group at base-
line, 8, 12, and 16 weeks was 5.3±0.6, 5.0±0.6, 4.2±0.4, and 
3.5±0.8, respectively (Table 2). There were significant dif-
ferences between the two groups in QoL and the mean 
change in QoL from baseline at week 8 (p＜0.001) (Table 
2,3). In both groups, there were significant differences be-
tween the QoL at baseline and that at week 16 (p＜0.001). 
At week 16, the mean change in the QoL from baseline was 
−1.7±1.2 and −1.8±1.0 in the 0.2 and 0.4 mg groups, re-
spectively, and there were no significant differences be-
tween the two groups (p=0.827) (Table 3).
　The mean Qmax of the 0.2 mg group at baseline, 8, 12, 
and 16 weeks was 7.9±2.6, 10.6±2.1, 11.1±2.7, and 12.8± 
2.0, respectively, and the mean Qmax of the 0.4 mg group 
at baseline, 8, 12, and 16 weeks was 7.4±1.9, 8.3±2.1, 
11.1±2.1, and 12.6±2.4, respectively (Table 2). There were 
significant differences between the two groups in Qmax 
and mean change in Qmax from baseline at week 8 (p＜ 
0.001) (Table 2, 3). In both groups, there were significant 
differences between the Qmax at baseline and that at week 
16 (p＜0.001). At week 16, the mean change in Qmax from 
baseline was 4.9±3.4 and 5.2±3.5 in the 0.2 and 0.4 mg 
groups, respectively, and there were no significant differ-
ences between the two groups (p=0.752) (Table 3).
　The mean postvoid residual urine volume (PVR) of the Korean J Urol 2011;52:479-484
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TABLE 4. Comparison of reported side effects between the 0.2 mg
group (tamsulosin 0.2 mg once daily) and the 0.4 mg group 
(tamsulosin 0.4 mg once daily)
0.2 mg group  0.4 mg group  p-value
Rhinitis
Rash
Abnormal
  ejaculation
Headache
Dizziness
0
1
4
2
3
1
0
2
1
1
Total (%) 10 (11.1) 5 (19.2) 0.321
FIG. 3. Change from baseline to week 8 and week 16 in total IPSS
(International Prostate Symptom Score) in the 0.2 and 0.4 mg 
group, 0.2 mg group: 8 weeks tamsulosin 0.2 mg once daily＋
additional 8 weeks tamsulosin 0.2 mg once daily, 0.4 mg group:
8 weeks tamsulosin 0.2 mg once daily＋additional 8 weeks 
tamsulosin 0.4 mg once daily.
FIG. 2. Mean total International Prostate Symptom Score (IPSS) 
at baseline and at week 16 in the 0.2 mg group (tamsulosin 0.2 
mg once daily) and the 0.4 mg group (tamsulosin 0.4 mg once 
daily) (n=116). 0.2 mg group (n=90): tamsulosin 0.2 mg once 
daily, 0.4 mg group (n=26): tamsulosin 0.4 mg once daily, 
a: p
＜0.001 versus baseline, 
b: p＜0.001 versus baseline.
0.2 mg group at baseline, 8, 12, and 16 weeks was 20.8±21.3, 
16.0±22.8, 15.8±20.0, and 13.5±17.7, respectively, and the 
mean PVR of the 0.4 mg group at baseline, 8, 12, and 16 
weeks was 19.6±21.3, 15.2±17.6, 15.4±22.1, and 12.7± 
20.5, respectively (Table 2). There were no significant dif-
ferences between the two groups in PVR at any week (Table 
2). In the 0.2 and 0.4 mg groups, there were significant dif-
ferences between the PVR at baseline and that at week 16 
(p＜0.001, p=0.028 respectively). At week 16, the mean 
change in the PVR from baseline was −7.4±16.4 and −6.9 
±15.2 in the 0.2 and 0.4 mg groups, respectively, and there 
were no significant differences between the two groups 
(p=0.897) (Table 3).
　Reported side effects were rhinitis, rash, abnormal ejacu-
lation, headache, and dizziness, and a total of 15 patients 
(12.9%) experienced these side effects. Ten patients in the 
0.2 mg group (11.1%) and 5 patients in the 0.4 mg group 
(19.2%) complained of side effects, but there were no sig-
nificant differences between the groups (p=0.321) (Table 4).
DISCUSSION
Complications such as acute urinary retention, bladder 
stone, urinary tract infection, and renal failure are the 
most common cause of the surgical management of BPH 
[11,12]. However, the expenses and complications asso-
ciated with the surgical treatment of BPH have led to the 
search for effective and safe medical therapies [13]. The ef-
ficacy and tolerability of alpha-1-adrenergic receptor an-
tagonists are of great interest in the treatment of BPH [14]. 
Pharmacologic and molecular studies have shown that the 
tension of prostatic smooth muscle is mediated by the al-
pha-1 subtype receptor and that this subtype is predom-
inant in prostatic stroma [15]. To reduce the adverse effects 
of alpha blockers, many clinical trials have been under-
taken to selectively target this receptor type. Of the re-
cently available alpha-blockers (terazosin, doxazosin, al-
fuzosin, and tamsulosin), tamsulosin has the most favor-
able tolerability, efficacy, and safety, and tamsulosin is the 
most widely used medicine in clinical practice [16]. 
Tamsulosin, which is a third-generation alpha-1-adrener-
gic receptor antagonist, is the only agent able to discrim-
inate between receptor subtypes [17]. Therefore, tamsulo-
sin may represent a good therapeutic alternative to open 
prostatectomy or transurethral resection of the prostate in 
the absence of absolute indications for surgical treatment 
[17]. Also, tamsulosin has only a negligible effect on blood 
pressure that does not appear to be clinically relevant, and 
it can be safely administered in combination with car-
diovascular drugs [18,19].
　Many long-term, placebo-controlled, double-blind stud-
ies evaluating tamsulosin in BPH have been carried out in 
Western countries. In Asian countries including Japan and 
Korea, however, there have been few studies about the effi-
cacy and tolerability of tamsulosin, and all studies were tri-
als of tamsulosin 0.2 mg. Therefore, we became interested 
in the efficacy of tamsulosin 0.4 mg in Korean men. 
Normally, 4 weeks of treatment with tamsulosin is enough Korean J Urol 2011;52:479-484
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to improve symptoms [20]. The 2002 Expertise Meeting in 
Urology (EMU) study confirmed that 8 weeks of tamsulosin 
treatment showed efficacy in comparison with a nontreat-
ment group. On the basis of these facts, the patients in this 
study were given 8 weeks of tamsulosin 0.2 mg before the 
assessment of efficacy to determine the 0.4 mg group at 
week 8. Many articles have used the primary criterion of 
improvement in urinary symptoms on the basis of improve-
ment in the IPSS of more than 4 scores or 20% to 25%. 
Accordingly, we defined ‘refractory LUTS’ as improvement 
in the IPSS or Qmax of less than 20%.
　To determine the efficacy and safety of tamsulosin for the 
medical treatment of BPH, numerous studies with doses 
of 0.2, 0.4, 0.6, and 0.8 mg have been done. The initial study 
by Abrams and associates was undertaken to help to estab-
lish the efficacy and safety of tamsulosin, as well as to de-
termine the optimum dosage for treatment [21]. Patients 
were randomly assigned to placebo, 0.2, 0.4, or 0.6 mg of 
tamsulosin once daily for 1 month. The greatest reduction 
in symptoms occurred in those taking either 0.4 or 0.6 mg 
compared with 0.2 mg and placebo [21]. The two highest 
doses also provided the greatest improvement in Qmax 
compared with placebo. There were no dose-related chan-
ges in vital signs or laboratory variables [21].
　Our study also showed that increasing the dosage im-
proved some of the test results, but the improvements were 
not as great as in the other studies mentioned above. We 
believe that these differences were because of the study de-
sign and group selection bias. We only increased the dosage 
of tamsulosin in patients who were refractory to low-dose 
tamsulosin. If initially we gave tamsulosin 0.4 mg to the 
patients who were not refractory to tamsulosin 0.2 mg once 
daily, we would have gotten more positive results.
　The most commonly reported adverse events that occur 
more frequently than with placebo are dizziness, rhinitis, 
and abnormal ejaculation. Asian men, especially Korean, 
Japanese, and Chinese men, are believed to have smaller 
BMIs than white men and accordingly increasing the dose 
of tamsulosin should result in more adverse effects than in 
white men. In our study, however, escalating the dose to 
0.4 mg improved the symptoms of BPH and the adverse ef-
fects were similar to those with 0.2 mg. These encouraging 
results suggest that it is safe and feasible to titrate the dos-
age of tamsulosin according to the severity of the patients’ 
symptoms without increasing the incidence of adverse 
effects.
　As far as we know, our study is the first prospective clin-
ical trial of the efficacy and tolerability of tamsulosin 0.4 
mg once daily in Korea. We demonstrated that tamsulosin 
0.4 mg has greater efficacy than tamsulosin 0.2 mg once 
daily in patients refractory to treatment with 0.2 mg and 
that the side effects appear to be similar to those with tam-
sulosin 0.2 mg.
Although our study was prospective, the double-dose 
group was too small in number (n=26). Accordingly, our 
study had limitations in analyzing the tolerability of the 
double-dose group. However, this is the initial study of tam-
sulosin 0.4 mg in Korea and the results are still prelimi-
nary. Long-term study will be carried out, which will give 
us more accurate data about the efficacy and tolerability 
of tamsulosin 0.4 mg.
CONCLUSIONS
Treating Korean patients with symptomatic BPH with 
tamsulosin 0.4 mg once daily was more efficacious than 
tamsulosin 0.2 mg once daily and showed similar rates of 
adverse effects. Especially, tamsulosin 0.4 mg once daily 
was shown to improve the IPSS, QoL, Qmax, and PVR in 
patients refractory to treatment with tamsulosin 0.2 mg 
once daily. Therefore, we believe it is safe to titrate the dos-
age of tamsulosin according to the severity of the patients’ 
symptoms without increasing the incidence of adverse 
effects.
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